EMEA-001971-PIP02-16-M02

Key facts

Active substance
Larotrectinib
Therapeutic area
Oncology
Decision number
P/0318/2019
PIP number
EMEA-001971-PIP02-16-M02
Pharmaceutical form(s)
  • Capsule, hard
  • Oral solution
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
  • Oral use
  • Gastric use
Contact for public enquiries
Bayer AG

Tel. +49 3046815333
E-mail: pediatrics.medical-affairs-europe@bayer.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating